Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Logothetis

Showing results (101-110 of 251) with videos related to

Pageof 26
Sort By:
Cancer Biology & Therapy|October 27, 2009
Dasatinib inhibits both osteoclast activation and prostate cancer PC-3-cell-induced osteoclast formationJohn C Araujo, Ann Poblenz, Paul Corn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2011
Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatmentVassiliki Tzelepi, Eleni Efstathiou, Sijin Wen, et al.
Ebiomedicine|January 26, 2020
Leukocyte telomere length is associated with aggressive prostate cancer in localized prostate cancer patientsJunfeng Xu, Wen-Shin Chang, Chia-Wen Tsai, et al.
European Urology|June 3, 2014
Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancerEleni Efstathiou, Mark Titus, Sijin Wen, et al.
Oncoimmunology|December 15, 2018
Genetic associations of T cell cancer immune response with tumor aggressiveness in localized prostate cancer patients and disease reclassification in an active surveillance cohortQinchuan Wang, Justin R Gregg, Jian Gu, et al.
Urologic Oncology|December 13, 2003
Treatment of refractory urothelial carcinoma with alternating paclitaxel, methotrexate, cisplatin (TMP) and 5-fluorouracil, alpha-interferon, cisplatin (FAP)Shi-Ming Tu, Randall E Millikan, Lance C Pagliaro, et al.
Oncotarget|October 31, 2015
Mitochondrial DNA copy number in peripheral blood leukocytes and the aggressiveness of localized prostate cancerHuakang Tu, Jian Gu, Qing H Meng, et al.
European Urology Oncology|August 15, 2019
Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer PatientsEleni Efstathiou, Mark Titus, Sijin Wen, et al.
BMC Cancer|September 8, 2016
The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory studyFarshid Dayyani, Amado J Zurita, Graciela M Nogueras-González, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2011
Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in boneEleni Efstathiou, Mark Titus, Dimitra Tsavachidou, et al.
Pageof 26

Showing results (101-110 of 251) with videos related to

Sort By:
Pageof 26
Cancer Biology & Therapy|October 27, 2009
Dasatinib inhibits both osteoclast activation and prostate cancer PC-3-cell-induced osteoclast formationJohn C Araujo, Ann Poblenz, Paul Corn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2011
Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatmentVassiliki Tzelepi, Eleni Efstathiou, Sijin Wen, et al.
Ebiomedicine|January 26, 2020
Leukocyte telomere length is associated with aggressive prostate cancer in localized prostate cancer patientsJunfeng Xu, Wen-Shin Chang, Chia-Wen Tsai, et al.
European Urology|June 3, 2014
Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancerEleni Efstathiou, Mark Titus, Sijin Wen, et al.
Oncoimmunology|December 15, 2018
Genetic associations of T cell cancer immune response with tumor aggressiveness in localized prostate cancer patients and disease reclassification in an active surveillance cohortQinchuan Wang, Justin R Gregg, Jian Gu, et al.
Urologic Oncology|December 13, 2003
Treatment of refractory urothelial carcinoma with alternating paclitaxel, methotrexate, cisplatin (TMP) and 5-fluorouracil, alpha-interferon, cisplatin (FAP)Shi-Ming Tu, Randall E Millikan, Lance C Pagliaro, et al.
Oncotarget|October 31, 2015
Mitochondrial DNA copy number in peripheral blood leukocytes and the aggressiveness of localized prostate cancerHuakang Tu, Jian Gu, Qing H Meng, et al.
European Urology Oncology|August 15, 2019
Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer PatientsEleni Efstathiou, Mark Titus, Sijin Wen, et al.
BMC Cancer|September 8, 2016
The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory studyFarshid Dayyani, Amado J Zurita, Graciela M Nogueras-González, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2011
Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in boneEleni Efstathiou, Mark Titus, Dimitra Tsavachidou, et al.
Pageof 26